The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
Correlation between mutation clearance and clinical response in elderly patients with acute myeloid leukemia (AML) treated with azacitidine and pracinostat.
 
Koichi Takahashi
Research Funding - MEI Pharma
 
Yasmin Abaza
No Relationships to Disclose
 
Ehab L. Atallah
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Pfizer
Research Funding - Millennium (Inst)
Travel, Accommodations, Expenses - MEI Pharma
 
Bruno C. Medeiros
Honoraria - Amgen; Astellas Pharma; Jazz Pharmaceuticals
Consulting or Advisory Role - Amgen; Astellas Pharma; Celator; Celgene; Jazz Pharmaceuticals; Novartis; Pfizer; Roche/Genentech
Research Funding - Astellas Pharma; Celator; Celgene; MEI Pharma; Merck/Schering Plough; Novartis; Roche/Genentech
Travel, Accommodations, Expenses - Astellas Pharma; Celator; Celgene; Jazz Pharmaceuticals; Novartis
 
Sam Khal
Honoraria - Alexion Pharmaceuticals
Consulting or Advisory Role - Alexion Pharmaceuticals
Speakers' Bureau - Alexion Pharmaceuticals
 
Martha Lucia Arellano
Research Funding - Cephalon (Inst)
 
Mrinal Patnaik
No Relationships to Disclose
 
Richard Ghalie
Employment - MEI Pharma
Leadership - Viracta Therapeutics
Stock and Other Ownership Interests - Amgen; Ligand
 
Guillermo Garcia-Manero
Research Funding - MEI Pharma